NYU Langone’S Perlmutter Cancer Center
Ribociclib regimen reduces recurrence risk in common breast cancer subtype
CHICAGO — The addition of ribociclib to endocrine therapy improved invasive DFS vs. endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.
Adjuvant regimen has ‘potential’ to change practice in high-risk liver cancer
Adjuvant treatment with atezolizumab and bevacizumab extended RFS compared with active surveillance among patients with hepatocellular carcinoma, according to study findings presented at AACR Annual Meeting.
Vaccine-immunotherapy combination extends RFS in high-risk melanoma
The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.
Data show ‘alarming’ shift in colorectal cancer to advanced stage, younger age at diagnosis
A greater percentage of colorectal cancer cases in the United States are being diagnosed at advanced stages, according to an American Cancer Society report.
Adjuvant nivolumab improves outcomes in high-risk urothelial cancer
SAN FRANCISCO — Adjuvant nivolumab improved outcomes compared with placebo for patients with high-risk muscle-invasive urothelial carcinoma, according to study results.
Rucaparib improves radiographic PFS in prostate cancer subgroup
SAN FRANCISCO — Rucaparib significantly improved radiographic PFS compared with physician’s choice of therapy for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.
Inflammation levels linked to survival in acute myeloid leukemia
Severe inflammation among individuals with acute myeloid leukemia limits their bodies’ ability to kill cancerous blood cells, according to study results.
Regorafenib extends survival in refractory advanced gastroesophageal cancer
Adding regorafenib to best supportive care significantly increased survival rates compared with placebo among patients with refractory advanced gastroesophageal cancer, results of the randomized, phase 3 INTEGRATE IIa trial showed.
Breast-conserving therapy may be viable option for multiple ipsilateral breast cancer
SAN ANTONIO — Lumpectomy followed by radiation therapy resulted in low rates of local recurrence at 5 years among women with multiple ipsilateral breast cancer, according to phase 2 study results.
Blinatumomab regimen may lead to ‘diminishing use of transplant’ for ALL subgroup
NEW ORLEANS — Blinatumomab extended survival when combined with chemotherapy for adults with minimal residual disease-negative, B-lineage acute lymphoblastic leukemia, according to a study presented at ASH Annual Meeting and Exposition.